{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:08:58Z","timestamp":1780722538372,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"SJIA Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For reasons poorly understood, and despite the availability of biological medications blocking IL-1 and IL-6 that have markedly improved overall disease control, children with Systemic Juvenile Idiopathic Arthritis (SJIA) are now increasingly diagnosed with life-threatening chronic complications, including hepatitis and lung disease (SJIA-LD). On October 3\u20134, 2019, a two-day meeting, <jats:italic>NextGen Therapies for Systemic Juvenile Idiopathic Arthritis (SJIA) &amp; macrophage activation syndrome (MAS<\/jats:italic>) organized by the <jats:italic>Systemic JIA Foundation<\/jats:italic> (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.systemicjia.org\/\">www.systemicjia.org\/<\/jats:ext-link>) in Washington, DC brought together scientists, clinicians, parents and FDA representatives with the objectives (1) to integrate clinical and research findings in MAS and SJIA-LD, and (2) to develop a shared understanding of this seemingly new pulmonary complication of SJIA. The current manuscript summarizes discussions and conclusions of the meeting.<\/jats:p>","DOI":"10.1186\/s12969-020-00444-7","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T23:06:55Z","timestamp":1594768015000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019"],"prefix":"10.1186","volume":"18","author":[{"given":"Scott W.","family":"Canna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant S.","family":"Schulert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"de Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermine","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gadina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaela","family":"Goldbach-Mansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Boutelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"DeBenedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei","family":"Grom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the NextGen 2019 Participants","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rae","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Riskalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sampath","family":"Prahalad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Alehashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Chandrakasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Vastert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Minerva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulayka","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Cupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"DelGaizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"444_CR1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/nrrheum.2011.68","volume":"7","author":"ED Mellins","year":"2011","unstructured":"Mellins ED, Macubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7:416\u201326.","journal-title":"Nat Rev Rheumatol"},{"key":"444_CR2","doi-asserted-by":"crossref","unstructured":"Rossi-Semerano L, Kone-Paut I. Is Still\u2019s disease an autoinflammatory syndrome? Int J Inflamm. 2012;2012:480373.","DOI":"10.1155\/2012\/480373"},{"key":"444_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","volume":"12","author":"AA Grom","year":"2016","unstructured":"Grom AA, Horne AC, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy: clues to pathogenesis and impact on diagnostic approaches. Nature Rev Rheumatol. 2016;12:259\u201368 PMID 27009539.","journal-title":"Nature Rev Rheumatol"},{"key":"444_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","volume":"76","author":"C Bracaglia","year":"2017","unstructured":"Bracaglia C, Kathy de Graaf K, Marafon DP, D\u2019Ario G, Guilhot F, Ferlin W, Prencipe G, Caiello I, Dav\u00ec D, Schulert G, Ravelli A, Grom AA, Min D, De Benedetti F. Elevated circulating levels of interferon-\u03b3 and interferon- induced chemokines characterize patients with macrophage activation syndrome complicating systemic JIA. Ann Rheum Dis. 2017;76:166\u201372.","journal-title":"Ann Rheum Dis"},{"key":"444_CR5","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","volume":"131","author":"ES Weiss","year":"2018","unstructured":"Weiss ES, Girard-Guyonvarc'h C, Holzinger D, de Jesus AA, Tariq Z, Picarsic J, Schiffrin EJ, Foell D, Grom AA, Ammann S, Ehl S, Hoshino T, Goldbach-Mansky R, Gabay C, Canna SW. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood. 2018;131:1442\u201355.","journal-title":"Blood."},{"key":"444_CR6","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulfraat N, Horneff G, Brik R, McCann L, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Grom AA, Magnusson OS, Abrams K, Kim D, Martini A, Lovell DJ. Two randomized trials of Canakinumab in systemic juvenile idiopathic arthritis. New Engl J Med. 2012;367:2396\u2013406.","journal-title":"New Engl J Med"},{"key":"444_CR7","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Ravelli A, Schneider WP, Wouters C, Zemel L, Burgos-Vargos R, Dolezalova P, Grom AA, Wulffraat N, Zuber Z, Zulian F, Lovell D, Martini A. Randomized trial of Tocilizumab in systemic juvenile idiopathic arthritis. New Engl J Med. 2012;367:2385\u201395.","journal-title":"New Engl J Med"},{"issue":"Suppl","key":"444_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/art.38472","volume":"66","author":"A Ravelli","year":"2014","unstructured":"Ravelli A, Schneider R, Weitzman S, Devlin C, Daimaru K, Yokota S, Takei S, De Benedetti F. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab. Arthritis Rheumatol. 2014;66(Suppl):83\u20134.","journal-title":"Arthritis Rheumatol"},{"key":"444_CR9","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3899\/jrheum.140288","volume":"42","author":"S Yokota","year":"2015","unstructured":"Yokota S, Itoh Y, Morio T, Sumitomo N, Daimaru K, Minota S. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol. 2015;42:712\u201322.","journal-title":"J Rheumatol"},{"key":"444_CR10","doi-asserted-by":"crossref","unstructured":"Grom AA, Ilowite NT, Pascual V, Brunner HI, Martinin A, Lovell D, Ruperto N, Leon K, Lheritier K, Abrams K. Canakinumab in systemic juvenile idiopathic arthritis: impact on the rate and clinical presentation of macrophage activation syndrome. Arthritis Rheumatol. 2016;68(1):218-28.","DOI":"10.1002\/art.39407"},{"key":"444_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/acr.21889","volume":"65","author":"Y Kimura","year":"2013","unstructured":"Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S, Rabinovich E, Riebschleger M, Ant\u00f3n J, Blier PR, Gerloni V, Hazen MM, Kessler E, Onel K, Passo MH, Rennebohm RM, Wallace CA, Woo P, Wulffraat N. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013;65:745\u201352.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"444_CR12","doi-asserted-by":"crossref","unstructured":"Schulert GS, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, Husami A, Watts A, Brunner HI, Huggins J, Mellins ED, Morgan EM, Ting T, Trapnell BC, Wikenheiser-Brokamp KA, Towe C, Grom AA. Systemic Juvenile Idiopathic Arthritis-Lung Disease: Characterization and Risk Factors. Arthritis Rheumatol. 2019; (in press).","DOI":"10.1002\/art.41073"},{"key":"444_CR13","doi-asserted-by":"crossref","unstructured":"Saper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, Canna S, Schulert G, Deterding R, Xu J, Leung AN, Bouzoubaa L, Abulaban K, Baszis K, Behrens EM, Birmingham J, Casey A, Cidon M, Cron RQ, De A, De Benedetti F, Ferguson I, Fishman MP, Goodman SI, Graham TB, Grom AA, Haines K, Hazen M, Henderson LA, Ho A, Ibarra M, Inman CJ, Jerath R, Khawaja K, Kingsbury DJ, Klein-Gitelman M, Lai K, Lapidus S, Lin C, Lin J, Liptzin DR, Milojevic D, Mombourquette J, Onel K, Ozen S, Perez M, Phillippi K, Prahalad S, Radhakrishna S, Reinhardt A, Riskalla M, Rosenwasser N, Roth J, Schneider R, Schonenberg-Meinema D, Shenoi S, Smith JA, S\u00f6nmez HE, Stoll ML, Towe C, Vargas SO, Vehe RK, Young LR, Yang J, Desai T, Balise R, Lu Y, Tian L, Bejerano G, Davis MM, Khatri P, Mellins ED; Childhood Arthritis and Rheumatology Research Alliance Registry Investigators. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis, 2019 (in press).","DOI":"10.1101\/19002923"},{"key":"444_CR14","doi-asserted-by":"crossref","unstructured":"de Jesus A, Hou Y, Brooks S, Malle L, Biancotto A, Huang Y, Calvo K, Marrero B, Moir S, Oler A, Deng Z, Montealegre Sanchez G, Canna S, Goldbach-Mansky R. Interferon signature and cytokine patterns define additional autoinflammatory diseases. J Clin Invest. 2020;130(4):1669-82.","DOI":"10.1172\/JCI129301"},{"issue":"10","key":"444_CR15","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/ng.3089","volume":"46","author":"SW Canna","year":"2014","unstructured":"Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y, DiMattia MA, Zaal KJ, Sanchez GA, Kim H, Chapelle D, Plass N, Huang Y, Villarino AV, Biancotto A, Fleisher TA, Duncan JA, O'Shea JJ, Benseler S, Grom A, Deng Z, Laxer RM, Goldbach-Mansky R. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet. 2014;46(10):1140\u20136.","journal-title":"Nat Genet"},{"key":"444_CR16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccm.2016.04.006","volume":"37","author":"T Suzuki","year":"2016","unstructured":"Suzuki T, Trapnell BC. Pulmonary alveolar Proteinosis syndrome. Clin Chest Med. 2016;37:431\u201340.","journal-title":"Clin Chest Med"},{"key":"444_CR17","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1182\/blood-2014-05-575225","volume":"125","author":"S Iriguchi","year":"2015","unstructured":"Iriguchi S, Kikuchi N, Kaneko S, Noguchi E, Morishima Y, Matsuyama M, Yoh K, Takahashi S, Nakauchi H, Ishii Y. T-cell-restricted T-bet overexpression induces aberrant hematopoiesis of myeloid cells and impairs function of macrophages in the lung. Blood. 2015;125:370\u201382.","journal-title":"Blood"},{"key":"444_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1586\/ers.10.74","volume":"4","author":"V Hadda","year":"2010","unstructured":"Hadda V, Khilnani GC. Lipoid pneumonia: an overview. Expert Rev Respir Med. 2010;4:799\u2013807.","journal-title":"Expert Rev Respir Med"},{"key":"444_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nri3600","volume":"14","author":"T Hussell","year":"2014","unstructured":"Hussell T, Bell TJ. Alveolar macrophages: plasticity in a tissue-specific context. Nat Rev Immunol. 2014;14:81\u201393.","journal-title":"Nat Rev Immunol"},{"key":"444_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jaci.2019.02.027","volume":"144","author":"EM Gordon","year":"2019","unstructured":"Gordon EM, Yao X, Xu H, Karkowsky W, Kaler M, Kalchiem-Dekel O, Barochia AV, Gao M, Keeran KJ, Jeffries KR, Levine SJ. Apolipoprotein E is a concentration-dependent pulmonary danger signal that activates the NLRP3 inflammasome and IL-1beta secretion by bronchoalveolar fluid macrophages from asthmatic subjects. J Allergy Clin Immunol. 2019;144:426\u2013441 e423.","journal-title":"J Allergy Clin Immunol"},{"key":"444_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1165\/rcmb.2016-0060TR","volume":"55","author":"X Yao","year":"2016","unstructured":"Yao X, Gordon EM, Figueroa DM, Barochia AV, Levine SJ. Emerging roles of Apolipoprotein E and Apolipoprotein A-I in the pathogenesis and treatment of lung disease. Am J Respir Cell Mol Biol. 2016;55:159\u201369.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"444_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1165\/rcmb.2017-0328ED","volume":"58","author":"AC McQuattie-Pimentel","year":"2018","unstructured":"McQuattie-Pimentel AC, Budinger GRS, Ballinger MN. Monocyte-derived alveolar macrophages: the dark side of lung repair? Am J Respir Cell Mol Biol. 2018;58:5\u20136.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"444_CR23","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1172\/JCI124615","volume":"129","author":"S Watanabe","year":"2019","unstructured":"Watanabe S, Alexander M, Misharin AV, Budinger GRS. The role of macrophages in the resolution of inflammation. J Clin Invest. 2019;129:2619\u201328.","journal-title":"J Clin Invest"},{"key":"444_CR24","unstructured":"Chen G, Schulert G, De Jesus A, Saper V, Schneider C, Trapnell B, Grom A, Goldbach-Mansky R, Mellins E, Khatri P, Canna S. multiplex Serum Analysis Identifies Potential Biomarkers of Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome, and Associated Pulmonary Alveolar Proteinosis: Evidence for Independently-regulated Hyperinflammatory and Eosinophilic Inflammation [abstract]. Arthritis Rheumatol. 2019;71(suppl 10). https:\/\/acrabstracts.org\/abstract\/multiplex-serum-analysis-identifies-potential-biomarkers-of-systemic-juvenile-idiopathic-arthritis-macrophage-activation-syndrome-and-associated-pulmonary-alveolar-proteinosis-evidence-for-independ\/. Accessed 1 Mar 2020."},{"issue":"1","key":"444_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cyto.2013.09.007","volume":"65","author":"T Wada","year":"2014","unstructured":"Wada T, Kanegane H, Ohta K, Katoh F, Imamura T, Nakazawa Y, Miyashita R, Hara J, Hamamoto K, Yang X, Filipovich AH, Marsh RA, Yachie A. Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency. Cytokine. 2014;65(1):74\u20138.","journal-title":"Cytokine."},{"issue":"4","key":"444_CR26","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jaci.2019.06.017","volume":"144","author":"Y Gernez","year":"2019","unstructured":"Gernez Y, de Jesus AA, Alsaleem H, Macaubas C, Roy A, Lovell D, Jagadeesh KA, Alehashemi S, Erdman L, Grimley M, Talarico S, Bacchetta R, Lewis DB, Canna SW, Laxer RM, Mellins ED, Goldbach-Mansky R, Weinacht KG. Severe autoinflammation in 4 patients with C-terminal variants in cell division control protein 42 homolog (CDC42) successfully treated with IL-1\u03b2 inhibition. J Allergy Clin Immunol. 2019;144(4):1122\u20135.","journal-title":"J Allergy Clin Immunol"},{"key":"444_CR27","doi-asserted-by":"publisher","unstructured":"Lam MT, Coppola S, OHF K, Prencipe G, Insalaco A, Cifaldi C, Brigida I, Zara E, Scala S, Di Cesare S, Martinelli S, Di Rocco M, Pascarella A, Niceta M, Pantaleoni F, Ciolfi A, Netter P, Carisey AF, Diehl M, Akbarzadeh M, Conti F, Merli P, Pastore A, Levi Mortera S, Camerini S, Farina L, Buchholzer M, Pannone L, Cao TN, Coban-Akdemir ZH, Jhangiani SN, Muzny DM, Gibbs RA, Basso-Ricci L, Chiriaco M, Dvorsky R, Putignani L, Carsetti R, Janning P, Stray-Pedersen A, Erichsen HC, Horne A, Bryceson YT, Torralba-Raga L, Ramme K, Rosti V, Bracaglia C, Messia V, Palma P, Finocchi A, Locatelli F, Chinn IK, Lupski JR, Mace EM, Cancrini C, Aiuti A, Ahmadian MR, Orange JS, De Benedetti F, Tartaglia M. A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. J Exp Med. 2019. https:\/\/doi.org\/10.1084\/jem.20190147 [Epub ahead of print].","DOI":"10.1084\/jem.20190147"},{"issue":"9","key":"444_CR28","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","volume":"49","author":"M Shimizu","year":"2010","unstructured":"Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, Toma T, Ohta K, Kasahara Y, Yachie A. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford). 2010;49(9):1645\u201353.","journal-title":"Rheumatology (Oxford)"},{"key":"444_CR29","doi-asserted-by":"crossref","unstructured":"Yasin S, Fall N, Brown RA, Henderlight M, Canna SW, Girard-Guyonvarc'h C, Gabay C, Grom AA, Schulert GS. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology. 2020;59(2):361-6.","DOI":"10.1093\/rheumatology\/kez282"},{"issue":"13","key":"444_CR30","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1182\/blood-2017-06-789552","volume":"131","author":"SW Canna","year":"2018","unstructured":"Canna SW, Girard C, Malle L, de Jesus A, Romberg N, Kelsen J, Surrey LF, Russo P, Sleight A, Schiffrin E, Gabay C, Goldbach-Mansky R, Behrens EM. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. 2017 may;139(5):1698-1701. Blood. 2018;131(13):1430\u201341.","journal-title":"Blood."},{"key":"444_CR31","doi-asserted-by":"publisher","unstructured":"Girard-Guyonvarc'h C, Palomo J, Martin P, Rodriguez E, Troccaz S, Palmer G, Gabay C. Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice. Rheumatology. 2019. https:\/\/doi.org\/10.1093\/rheumatology\/kez284 [Epub ahead of print].","DOI":"10.1093\/rheumatology\/kez284"},{"key":"444_CR32","doi-asserted-by":"crossref","unstructured":"Yasin S, Solomon K, Canna SW, Girard-Guyonvarc'h C, Gabay C, Schiffrin E, Sleight A, Grom AA, Schulert GS. IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome. Rheumatology. 2020;59(2):442-5.","DOI":"10.1093\/rheumatology\/kez284"},{"key":"444_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz DM, Bonelli M, Gadina M, O'Shea JJ. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25\u201336.","journal-title":"Nat Rev Rheumatol"},{"key":"444_CR34","doi-asserted-by":"crossref","unstructured":"De Benedetti F, Brogan P, Grom AA, Quartier P, Schneider R, De Graaf K, Jacqmin P, Ballabio M, de Min C. Emapalumab, an interferon gamma blocking antibody in patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. EULAR Annu Meet. 2019;78:178.","DOI":"10.1136\/annrheumdis-2019-eular.3341"},{"key":"444_CR35","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1182\/blood-2004-08-2997","volume":"105","author":"AD Billiau","year":"2005","unstructured":"Billiau AD, Roskams T, Van Damme-Lombaerts R, et al. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood. 2005;105:1648.","journal-title":"Blood"},{"key":"444_CR36","doi-asserted-by":"crossref","unstructured":"Prencipe G, Bracaglia C, Caiello I, Pascarella A, Francalanci P, Pardeo M, Meneghel A, Martini G, Rossi MN, Insalaco A, Marucci G, Nobili V, Spada M, Zulian F, De Benedetti F. The interferon-gamma pathway is selectively upregulated in the liver of patients with secondary hemophagocytic lymphohistiocytosis. PLoS One. 2019;14(12):e0226043.","DOI":"10.1371\/journal.pone.0226043"},{"key":"444_CR37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","volume":"75","author":"A Ravelli","year":"2016","unstructured":"Ravelli A, Minoia F, Dav\u00ec S, Horne A, Bovis F, Pistorio A, Aric\u00f2 M, Avcin T, Behrens EM, De Benedetti F, Filipovic L, Grom AA, Henter JI, Ilowite NT, Jordan MB, Khubchandani R, Kitoh T, Lehmberg K, Lovell DJ, Miettunen P, Nichols KE, Ozen S, Pachlopnik-Schmid J, Ramanan AV, Russo R, Schneider R, Sterba G, Uziel Y, Wallace C, Wouters C, Wulffraat N, Demirkaya E, Brunner HI, Martini A, Ruperto N, Cron RQ. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism\/ American College of Rheumatology\/ Paediatric Rheumatology International Trials Organization Collaborative Initiative. Ann Rheum Dis. 2016;75:481\u20139.","journal-title":"Ann Rheum Dis"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-020-00444-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-020-00444-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-020-00444-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T23:24:15Z","timestamp":1626305055000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-020-00444-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":37,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["444"],"URL":"https:\/\/doi.org\/10.1186\/s12969-020-00444-7","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"26 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed the manuscript and provided their consent to publish. All the patients mentioned in the manuscript gave their permissions to use full names.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Canna received clinical trial support from AB2Bio. Dr. Schulert has received consulting fees from SOBI and Novartis (less than $10,000 each). Dr. Brunner has received consulting fees from Bristol-Myers Squibb, Pfizer, Janssen, Eli Lilly, Roche, and Novartis (less than $10,000 each). Dr. Grom has received consulting fees from SOBI and Novartis (less than $10,000 each) and research support from SOBI, Novartis, and AB2 Bio. Dr. Gadina has a Collaborative Research and Development Agreement related to JAK inhibitors with Pfizer. Dr. De Benedetti has received research grants from Abbvie, Pfizer, Eli-Lilly, Roche, Novartis, NovImmune, Sanofi, and SOBI. Dr. Rashmi Sinha serves as the president of <i>the SJIA Foundation<\/i>. No other disclosures relevant to this article were reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}